Targeting the mitogen-activated protein kinase cascade to treat cancer.

BRAF mutation predicts sensitivity to MEK inhibition. Nature (2005) 17.14

Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer (2009) 9.33

A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. Genes Dev (2007) 5.07

Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. J Clin Invest (2008) 4.13

Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. J Clin Invest (2009) 3.55

Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH. Science (2015) 2.89

AlphaB-crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer. J Clin Invest (2006) 2.74

Genetic predictors of MEK dependence in non-small cell lung cancer. Cancer Res (2008) 2.71

KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer. Mol Cancer Ther (2009) 2.22

Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic. J Clin Invest (2008) 2.17

Control of mitotic spindle angle by the RAS-regulated ERK1/2 pathway determines lung tube shape. Science (2011) 2.12

Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF. Oncogene (2011) 2.10

ERK1 and ERK2 mitogen-activated protein kinases affect Ras-dependent cell signaling differentially. J Biol (2006) 2.04

Potent inhibition of thyroid cancer cells by the MEK inhibitor PD0325901 and its potentiation by suppression of the PI3K and NF-kappaB pathways. Thyroid (2008) 1.93

From basic research to clinical development of MEK1/2 inhibitors for cancer therapy. J Hematol Oncol (2010) 1.92

The multifaceted role of MTDH/AEG-1 in cancer progression. Clin Cancer Res (2009) 1.89

Protein kinases as drug targets in trypanosomes and Leishmania. Biochim Biophys Acta (2005) 1.87

High level of AKT activity is associated with resistance to MEK inhibitor AZD6244 (ARRY-142886). Cancer Biol Ther (2009) 1.86

Direct activation of TACE-mediated ectodomain shedding by p38 MAP kinase regulates EGF receptor-dependent cell proliferation. Mol Cell (2010) 1.85

MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors. J Clin Invest (2012) 1.83

Targeted therapy for BRAFV600E malignant astrocytoma. Clin Cancer Res (2011) 1.79

Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response. Clin Cancer Res (2010) 1.77

Distinct genetic alterations in the mitogen-activated protein kinase pathway dictate sensitivity of thyroid cancer cells to mitogen-activated protein kinase kinase 1/2 inhibition. Thyroid (2009) 1.73

Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo. Br J Haematol (2010) 1.73

Cotargeting survival signaling pathways in cancer. J Clin Invest (2008) 1.68

Hepatitis B virus X protein represses miRNA-148a to enhance tumorigenesis. J Clin Invest (2013) 1.68

Polyphenols and human health: prevention of disease and mechanisms of action. Nutrients (2010) 1.66

MAP kinase pathways: the first twenty years. Biochim Biophys Acta (2006) 1.65

Novel mechanisms of early upper and lower urinary tract patterning regulated by RetY1015 docking tyrosine in mice. Development (2012) 1.64

SCF-mediated mast cell infiltration and activation exacerbate the inflammation and immunosuppression in tumor microenvironment. Blood (2008) 1.63

Forkhead box M1 transcription factor: a novel target for cancer therapy. Cancer Treat Rev (2009) 1.63

Mutation analysis of BRAF, MEK1 and MEK2 in 15 ovarian cancer cell lines: implications for therapy. PLoS One (2007) 1.56

Genomic complexity and AKT dependence in serous ovarian cancer. Cancer Discov (2012) 1.50

Mediating ERK 1/2 signaling rescues congenital heart defects in a mouse model of Noonan syndrome. J Clin Invest (2007) 1.48

Formation of a polarised primitive endoderm layer in embryoid bodies requires fgfr/erk signalling. PLoS One (2014) 1.44

Emerging roles of PDGF-D signaling pathway in tumor development and progression. Biochim Biophys Acta (2010) 1.42

Matrix metalloproteinase-activated anthrax lethal toxin demonstrates high potency in targeting tumor vasculature. J Biol Chem (2007) 1.41

Control of cell survival and proliferation by mammalian eukaryotic initiation factor 4B. Mol Cell Biol (2010) 1.41

ERK and AKT signaling cooperate to translationally regulate survivin expression for metastatic progression of colorectal cancer. Oncogene (2013) 1.40

Cellular signaling perturbation by natural products. Cell Signal (2009) 1.36

Comparative expression pathway analysis of human and canine mammary tumors. BMC Genomics (2009) 1.35

Activated MEK suppresses activation of PKR and enables efficient replication and in vivo oncolysis by Deltagamma(1)34.5 mutants of herpes simplex virus 1. J Virol (2006) 1.35

Role of exosomes released by chronic myelogenous leukemia cells in angiogenesis. Int J Cancer (2011) 1.34

Ribosomal S6 kinase 2 is a key regulator in tumor promoter induced cell transformation. Cancer Res (2007) 1.33

Prostaglandin E2 promotes lung cancer cell migration via EP4-betaArrestin1-c-Src signalsome. Mol Cancer Res (2010) 1.32

Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab. Cancer Biol Ther (2011) 1.31

Raf and MEK protein kinases are direct molecular targets for the chemopreventive effect of quercetin, a major flavonol in red wine. Cancer Res (2008) 1.30

Unique MAP Kinase binding sites. Biochim Biophys Acta (2007) 1.29

Targeted therapy for metastatic renal cell carcinoma. Br J Cancer (2006) 1.29

pHUSH: a single vector system for conditional gene expression. BMC Biotechnol (2007) 1.27

Sorafenib potently inhibits papillary thyroid carcinomas harboring RET/PTC1 rearrangement. Clin Cancer Res (2008) 1.27

MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road. Nat Rev Cancer (2015) 1.27

The Role of PPARs in Cancer. PPAR Res (2008) 1.26

Growth-inhibitory and antiangiogenic activity of the MEK inhibitor PD0325901 in malignant melanoma with or without BRAF mutations. Neoplasia (2009) 1.23

Erk2 phosphorylation of Drp1 promotes mitochondrial fission and MAPK-driven tumor growth. Mol Cell (2015) 1.23

Activation of multiple signaling pathways causes developmental defects in mice with a Noonan syndrome–associated Sos1 mutation. J Clin Invest (2010) 1.21

Chitinase 3-like 1 promotes macrophage recruitment and angiogenesis in colorectal cancer. Oncogene (2011) 1.19

Enhanced inhibition of ERK signaling by a novel allosteric MEK inhibitor, CH5126766, that suppresses feedback reactivation of RAF activity. Cancer Res (2013) 1.19

RAD001 (everolimus) inhibits tumour growth in xenograft models of human hepatocellular carcinoma. J Cell Mol Med (2008) 1.19

Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial. Clin Cancer Res (2013) 1.19

Glioblastoma multiforme: State of the art and future therapeutics. Surg Neurol Int (2014) 1.18

ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities. Cell (2012) 1.18

Frequent genetic abnormalities of the PI3K/AKT pathway in primary ovarian cancer predict patient outcome. Genes Chromosomes Cancer (2011) 1.18

Exosomes from drug-resistant breast cancer cells transmit chemoresistance by a horizontal transfer of microRNAs. PLoS One (2014) 1.18

A role for K-ras in conferring resistance to the MEK inhibitor, CI-1040. Neoplasia (2005) 1.18

Kinase-activating and kinase-impaired cardio-facio-cutaneous syndrome alleles have activity during zebrafish development and are sensitive to small molecule inhibitors. Hum Mol Genet (2009) 1.13

Synergistic combinations of signaling pathway inhibitors: mechanisms for improved cancer therapy. Drug Resist Updat (2009) 1.12

193-nm photodissociation of singly and multiply charged peptide anions for acidic proteome characterization. Proteomics (2011) 1.11

ERK activation causes epilepsy by stimulating NMDA receptor activity. EMBO J (2007) 1.10

The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models. Br J Cancer (2012) 1.09

MEK inhibitor PD0325901 significantly reduces the growth of papillary thyroid carcinoma cells in vitro and in vivo. Mol Cancer Ther (2010) 1.08

Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies. Drug Resist Updat (2007) 1.08

Exercise modulation of the host-tumor interaction in an orthotopic model of murine prostate cancer. J Appl Physiol (1985) (2012) 1.08

RSK in tumorigenesis: connections to steroid signaling. Steroids (2010) 1.08

Selective role for Mek1 but not Mek2 in the induction of epidermal neoplasia. Cancer Res (2009) 1.08

Selective, rapid and optically switchable regulation of protein function in live mammalian cells. Nat Chem (2015) 1.08

Treatment options for patients with triple-negative breast cancer. J Hematol Oncol (2010) 1.07

Construction of a cancer-perturbed protein-protein interaction network for discovery of apoptosis drug targets. BMC Syst Biol (2008) 1.07

Cotargeting MAPK and PI3K signaling with concurrent radiotherapy as a strategy for the treatment of pancreatic cancer. Mol Cancer Ther (2012) 1.06

3'-deoxy-3'-[18F]fluorothymidine positron emission tomography is a sensitive method for imaging the response of BRAF-dependent tumors to MEK inhibition. Cancer Res (2007) 1.04

Exploiting cellular pathways to develop new treatment strategies for AML. Cancer Treat Rev (2010) 1.03

Regulation of MDMX expression by mitogenic signaling. Mol Cell Biol (2008) 1.01

Activation of MEK1 or MEK2 isoform is sufficient to fully transform intestinal epithelial cells and induce the formation of metastatic tumors. BMC Cancer (2008) 1.01

Activation of extracellular regulated kinases (ERK1/2) but not AKT predicts poor prognosis in colorectal carcinoma and is associated with k-ras mutations. Virchows Arch (2007) 1.01

FIZZ2/RELM-β induction and role in pulmonary fibrosis. J Immunol (2011) 1.01

Toxin-based therapeutic approaches. Toxins (Basel) (2010) 1.00

Sym004, a novel EGFR antibody mixture, can overcome acquired resistance to cetuximab. Neoplasia (2013) 1.00

Phosphoproteomic characterization of DNA damage response in melanoma cells following MEK/PI3K dual inhibition. Proc Natl Acad Sci U S A (2013) 0.98

Loss of PTEN permits CXCR4-mediated tumorigenesis through ERK1/2 in prostate cancer cells. Mol Cancer Res (2010) 0.98

Bcl2-associated athanogene 3 interactome analysis reveals a new role in modulating proteasome activity. Mol Cell Proteomics (2013) 0.98

Dual blockade of the Hedgehog and ERK1/2 pathways coordinately decreases proliferation and survival of cholangiocarcinoma cells. J Cancer Res Clin Oncol (2006) 0.98

Inhibition of ERK1/2 and activation of liver X receptor synergistically induce macrophage ABCA1 expression and cholesterol efflux. J Biol Chem (2009) 0.98

Differential Expression of Key Signaling Proteins in MCF10 Cell Lines, a Human Breast Cancer Progression Model. Mol Cell Pharmacol (2012) 0.98

Nicotine promotes proliferation of human nasopharyngeal carcinoma cells by regulating α7AChR, ERK, HIF-1α and VEGF/PEDF signaling. PLoS One (2012) 0.97

New targets and challenges in the molecular therapeutics of cancer. Br J Clin Pharmacol (2006) 0.97

PPAR-γ agonists and their effects on IGF-I receptor signaling: Implications for cancer. PPAR Res (2009) 0.96

YB-1 is a Transcription/Translation Factor that Orchestrates the Oncogenome by Hardwiring Signal Transduction to Gene Expression. Transl Oncogenomics (2007) 0.96

RSK2 as a key regulator in human skin cancer. Carcinogenesis (2012) 0.96

The G2 p38-mediated stress-activated checkpoint pathway becomes attenuated in transformed cells. Curr Biol (2007) 0.96

Altered dendritic cell phenotype in response to Leishmania amazonensis amastigote infection is mediated by MAP kinase, ERK. Am J Pathol (2009) 0.96

Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol (2004) 6.61

Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol (2005) 2.32

Activation of SGK1 by HGF, Rac1 and integrin-mediated cell adhesion in MDCK cells: PI-3K-dependent and -independent pathways. J Cell Sci (2002) 1.05

Modulation of HeLa cells spreading by the non-receptor tyrosine kinase ACK-2. J Cell Biochem (2002) 0.87

The mitogen-activated protein kinase pathway for molecular-targeted cancer treatment. Recent Results Cancer Res (2007) 0.82

Biomarker assays for phosphorylated MAP kinase. Their utility for measurement of MEK inhibition. Methods Mol Med (2003) 0.81